Randomized Intervention for Children With Vesicoureteral Reflux (RIVUR)
Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
In this 2-year, multisite, randomized, placebo-controlled trial involving 607 children with
vesicoureteral reflux that was diagnosed after a first or second febrile or symptomatic
urinary tract infecton, we evaluated the efficacy of Trimethoprim-Sulfamethoxazole (TMP-SMZ)
prophylaxis in preventing recurrences (primary outcome). Secondary outcomes were renal
scarring, treatment failure (a composite of recurrences and scarring), and antimicrobial
resistance.
Phase:
Phase 3
Details
Lead Sponsor:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborator:
University of North Carolina, Chapel Hill
Treatments:
Sulfamethoxazole Trimethoprim Trimethoprim, Sulfamethoxazole Drug Combination